Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
Future Oncol
; 16(7): 269-279, 2020 Mar.
Article
em En
| MEDLINE
| ID: mdl-32043375
ABSTRACT
Aim:
Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients.Methods:
Records of HER2+ BC treated in 2000-2017 were reviewed.Results:
283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio 4.7; 95% CI 3.5-6.4). Prognostic factors were number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025).Conclusion:
Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Neoplasias do Sistema Nervoso Central
/
Receptor ErbB-2
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália